MATEON THERAPEUTICS, INC. (OTCMKTS:MATN) Files An 8-K Other Events
Item8.01 Other Events.
On March15, 2017, Mateon Therapeutics, Inc. (Mateon) issued a
press release announcing initial data from the third dose cohort
of its Phase 1b study of OXi4503 in Relapsed/Refractory Acute
Myeloid Leukemia. OXi4503 is one of Mateons two vascular
disrupting agents (VDAs) currently in clinical development.
A copy of the press release is attached hereto as Exhibit 99.1
and is incorporated herein by reference.
Item9.01 Financial Statements and Exhibits.
The following exhibit is furnished with this report:
| ExhibitNumber | Description | |
| 99.1 | Press Release dated March 15, 2017. |
About MATEON THERAPEUTICS, INC. (OTCMKTS:MATN)
Mateon Therapeutics, Inc., formerly OXiGENE, Inc., is a biopharmaceutical company. The Company is focused on the development of vascular disrupting agents (VDAs) for the treatment of cancer. The Company is engaged in developing two clinical stage investigational drugs: VDAs-CA4P and OXi4503. Its lead compound is CA4P, which is also known as combretastatin A4-phosphate, fosbretabulin tromethamine, fosbretabulin and ZYBRESTAT. VDAs selectively targets the vasculature of cancer tumors and obstructs a tumor’s blood supply without disrupting the blood supply to normal tissues. VDAs are in a class of drugs called vascular targeted therapies (VTTs), which also includes anti-angiogenic agents (AAs). CA4P is a reversible tubulin binding agent that selectively targets the endothelial cells that make up the blood vessel walls in solid tumors. The Company is pursuing the development of a product candidate, OXi4503, which is a dual-mechanism VDA. MATEON THERAPEUTICS, INC. (OTCMKTS:MATN) Recent Trading Information
MATEON THERAPEUTICS, INC. (OTCMKTS:MATN) closed its last trading session 00.000 at 0.668 with 988,527 shares trading hands.
